Press Releases

Year

Mar 13, 2020

Applied Therapeutics Reports Fourth Quarter and Year-end 2019 Financial Results

NEW YORK , March 13, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the

Mar 10, 2020

Applied Therapeutics to Present at the Barclays Global Healthcare Conference

NEW YORK , March 10, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at

Mar 03, 2020

Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer

NEW YORK , March 03, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today announced the appointment of Adam Hansard as Chief Commercial Officer. Mr.

Feb 26, 2020

Applied Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

NEW YORK , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at

Jan 28, 2020

Applied Therapeutics, Inc. Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares of Common Stock

NEW YORK , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has

Jan 23, 2020

Applied Therapeutics, Inc. Announces Upsizing and Pricing of Public Offering of 2,741,489 Shares of Common Stock

NEW YORK , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the

Jan 21, 2020

Applied Therapeutics, Inc. Announces Offering of 1,750,000 Shares of Common Stock

NEW YORK , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it

Jan 08, 2020

Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients

AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 28 of 28

Desktop - About Us

Desktop - Pipeline

Desktop - Patients & Caregivers

Desktop - Investor Menu

Mobile Header Links

Footer Disclaimer Links

Social Links

Social Links

Footer Disclaimer Links